Compound: Antalarmin
SMILES: n1c(N(CCCC)CC)c2c(n(-c3c(cc(C)cc3C)C)c(c2C)C)nc1C
InChIKey: IXPROWGEHNVJOY-UHFFFAOYSA-N
Synonyms: Antalarmin, 157284-96-3, G3DNT7X7YL, 7H-Pyrrolo(2,3-d)pyrimidin-4-amine, N-butyl-N-ethyl-2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-, CHEBI:139557, DTXSID50166241, 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-butyl-N-ethyl-2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-, N-butyl-N-ethyl-2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)pyrrolo(3,2-e)pyrimidin-4-amine, N-butyl-N-ethyl-2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)pyrrolo[3,2-e]pyrimidin-4-amine, RefChem:112939, DTXCID7088732, N-butyl-N-ethyl-(2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo(2,3-d)pyrimidin-4-yl)amine, N-butyl-N-ethyl-7-mesityl-2,5,6-trimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine, N-butyl-N-ethyl-2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)pyrrolo[2,3-d]pyrimidin-4-amine, CHEMBL296641, Butyl-ethyl-[2,5,6-trimethyl-7-(2,4,6-trimethyl-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-amine, N-BUTYL-N-ETHYL-2,5,6-TRIMETHYL-7-(2,4,6-TRIMETHYLPHENYL)PYRROLO(2,3-D)PYRIMIDIN-4-AMINE, UNII-G3DNT7X7YL, SCHEMBL466243, GTPL3489, orb1739047, SCHEMBL29832078, EX-A6937A, C24H34N4, BDBM50074501, NSC715590, NSC-715590, NCGC00165732-01, DA-50491, FA183627, N-butyl-N-ethyl-2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine, NCI60_039940, HY-124475, CS-0086611, H42650, Q4770927, 7H-Pyrrolo[2, N-butyl-N-ethyl-2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-, Butyl-ethyl-[2,5,6-trimethyl-7-(2,4,6-trimethyl-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-amine(antalarmin), N-butyl-N-ethyl-[2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-7h-pyrrolo[2,3-d]pyrimidin4-yl]-amine, N-butyl-N-ethyl-2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)- 7H-pyrrolo[2,3-d]pyrimidin-4-amine
Theoretical properties:
molecular_formula: C24H34N4
molecular_weight: 378.6 g/mol
exact_mass: 378.27834710 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 0
hydrogen_bond_acceptor_count: 3
rotatable_bond_count: 6
heavy_atom_count: 28
topological_polar_surface_area: 34 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
Descriptions:
{"pubchem": "Antalarmin is a pyrrolopyrimidine that is 7H-pyrrolo[2,3-d]pyrimidin-4-amine which is substituted by methyl groups at positions 2, 5, and 6, by a mesityl group at position 7, and in which the amino substituent at position 4 has been substituted by ethyl and butyl groups. It is an antagonist of corticotropin-releasing factor 1 (CRF-1) receptors (Ki = 1 nM). It has a role as a corticotropin-releasing factor receptor antagonist. It is a pyrrolopyrimidine and a tertiary amino compound.", "chebi": "A pyrrolopyrimidine that is 7<em>H</em>-pyrrolo[2,3-<em>d</em>]pyrimidin-4-amine which is substituted by methyl groups at positions 2, 5, and 6, by a mesityl group at position 7, and in which the amino substituent at position 4 has been substituted by ethyl and butyl groups. It is an antagonist of corticotropin-releasing factor 1 (CRF-1) receptors (Ki = 1 nM).", "chembl": "ANTALARMIN is a small molecule listed in the ChEMBL database but has not progressed to an approved clinical phase.", "wikipedia": "Antalarmin (CP-156,181) is a drug that acts as a CRH1 antagonist.\nCorticotropin-releasing hormone (CRH), also known as Corticotropin-releasing factor, is an endogenous peptide hormone released in response to various triggers such as chronic stress and drug addiction. Such triggers result in the release of corticotropin (ACTH), another hormone involved in the physiological response to stress. Chronic release of CRH and ACTH is believed to be directly or indirectly involved in many of the harmful physiological effects of chronic stress, such as excessive glucocorticoid release, stomach ulcers, anxiety, diabetes mellitus, osteoporosis, depression, and development of high blood pressure and consequent cardiovascular problems.\nAntalarmin is a non-peptide drug that blocks the CRH1 receptor, and, as a consequence, reduces the release of ACTH in response to chronic stress. This has been demonstrated in animals to reduce the behavioral responses to stressful situations, and it is proposed that antalarmin itself, or more likely newer CRH1 antagonist drugs still under development, could be useful for reducing the adverse health consequences of chronic stress in humans, as well as having possible uses in the treatment of conditions such as anxiety, depression, and drug addiction."}